Cargando…
Current european regulatory perspectives on insulin analogues
Insulin analogues are increasingly considered as an alternative to human insulin in the therapy of diabetes mellitus. Insulin analogues (IAs) are chemically different from human insulin and may have different pharmacokinetic or pharmacodynamic properties. The significance of the modifications of the...
Autores principales: | Enzmann, Harald G, Weise, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224552/ https://www.ncbi.nlm.nih.gov/pubmed/21736748 http://dx.doi.org/10.1186/1758-5996-3-14 |
Ejemplares similares
-
Promoting Safe Early Clinical Research of Novel Drug Candidates: A European Union Regulatory Perspective
por: Ponzano, Stefano, et al.
Publicado: (2017) -
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective
por: Eckstein, Niels, et al.
Publicado: (2014) -
Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019) -
Biosimilar insulins: a European perspective
por: DeVries, J H, et al.
Publicado: (2015) -
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015)